Table 1.
Summary of included case reports, with basic demographics, comorbidities and final ACTD diagnosis
| Title | Country | Gender | Mean age (years) | Comorbidities | ACTD diagnosis (as reported in article) |
|---|---|---|---|---|---|
| Zhang et al. 2022 [22] | USA | F | 58 | No | COVID‐19-associated myositis |
| Ramachandran et al. 2022 [30] | USA | M | 53 | Hypertension, CKD 3, cholecystectomy | SLE |
| Pereira et al. 2022 [40] | India | M | 57 | Unknown | Anti-synthetase syndrome |
| Okayasu et al. 2022 [23] | Japan | M | 89 | Hypertension, angina pectoris, dementia, clavicle fracture, previous lumbar vertebral compression fracture | Myositis and febrile neutropenia |
| Okada et al. 2022 [24] | Japan | F | 64 | Unknown | Dermatomyositis |
| Nunes et al. 2022 [38] | Portugal | F | 70 | Hypertension | Toxic epidermal necrolysis-like subacute cutaneous lupus |
| Kazzi et al. 2022 [31] | USA | M | 37 | No | SLE |
| Holzer et al. 2022 [19] | Germany | F | 20 | Unknown | Dermatomyositis |
| Giuggioli et al. 2022 [41] | Italy | F | 53 | Unknown | Raynaud's and systemic sclerosis |
| Chandra & Kahaleh 2022 [42] | USA | F | 48 | Anxiety, depression | Systemic Sclerosis |
| Bouchard Marmen et al. 2022 [43] | Canada | M | 62 | Unknown | Anti-synthetase syndrome |
| Blum et al. 2022 [44] | USA | M | 67 | None | Diffuse systemic sclerosis |
| Assar et al. 2022 [32] | Iran | F | 38 | Anxiety | SLE |
| Anderle et al. 2022 [45] | Austria | M | 20 | Unknown | Anti-MDA5 dermatomyositis |
| Amin et al. 2022 [27] | Pakistan | F | 52 | None | Polymyositis |
| Ali et al. 2022 [33] | Pakistan | F | 22 | Unknown | MCTD associated with a flare of lupus nephritis |
| Zamani et al. 2021 [34] | Iran | M | 39 | None | SLE |
| Slimani et al. 2021 [35] | Morocco | F | 23 | None | SLE and aPLS |
| Dadras et al. 2021 [25] | Iran | F | 58 | Diabetes mellitus, hypothyroidism, coronary artery | Dermatomyositis |
| Lokineni et al. 2021 [29] | USA | M | 51 | None | Necrotizing Myositis |
| Keshtkarjahromi et al. 2021 [46] | USA | F | 65 | Psoriasis, hypertension, hyperlipidaemia | MDA5-positive dermatomyositis complicated by MAS |
| Fineschi S 2021 [47] | Sweden | M | 47 | Unknown | Systemic Sclerosis |
| Borges et al. 2021 [20] | Brazil | F | 36 | Unknown | Dermatomyositis |
| Assar et al. 2021 [26] | Iran | F | 45 | OCD, hypothyroidism, migraine | Neutrophilic myositis |
| Ali et al. 2021 [36] | USA | F | 25 | Asthma, depression | SLE (complicated by HLH) |
| Aldaghlawi et al. 2021 [28] | USA | F | 69 | Stage IV chronic lymphocytic leukaemia | Myositis |
| Sacchi et al. 2020 [21] | Italy | F | 77 | Obesity, monoclonal gammopathy, diabetes mellitus, COPD, atrial fibrillation, CKD, cardiac failure | Myositis |
| Bonometti et al. 2020 [37] | Italy | F | 85 | None | SLE |
CKD chronic kidney disease, SLE systemic lupus erythematosus, MDA5 melanoma differentiation-associated protein 5, COPD chronic obstructive pulmonary disease